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Objective: Establishment of an 
immunocompetent mouse model 
representing the typical 
progressive stages observed in 
malignant human gliomas for the 
in vivo evaluation of novel target-
specific regimens.
Methods: Isolated clones from 
tumours that arose spontaneously 
in GFAP-v-src transgenic mice 
were used to develop a 
transplantable brain tumour model in syngeneic B6C3F1 mice. STAT3 
protein was knocked down by 
infection of tumour cells with 
replication-defective lentivirus 
encoding STAT3-siRNA. Apoptosis 
is designed to be induced by 
soluble recombinant TRAIL + 
chemical Bcl-2/Bcl-xL inhibitors.
Results: Striatal implantation of 
105 mouse tumour cells resulted 
in the robust development of 
microscopically (2 – 3 mm) 
infiltrating malignant gliomas. 
Immunohistochemically, the 
gliomas displayed the astroglial 
marker GFAP and the oncogenic 
form of STAT3 (Tyr-705-
phosphorylated) which is found in 
many malignancies including 
gliomas. Phosphorylated STAT3 
was particularly prominent in the 
nucleus but was also found at the 
plasma membrane of peripherally 
infiltrating glioma cells. To 
evaluate the role of STAT3 in 
tumour progression, we stably 
expressed siRNA against STAT3 in 
several murine glioma cell lines. 
The effect of STAT3 depletion on 
proliferation, invasion and survival 
will be first assessed in vitro and 
subsequently after transplantation 
in vivo. Upstream and 
downstream components of the 
STAT3 signalling pathway as well 
as possible non-specific side 
effects of STAT3-siRNA expression 
after lentiviral infection will be 
examined, too.
Conclusions: Its high rate of 
engraftment, its similarity to the 
malignant glioma of origin, and its 
rapid locally invasive growth should make this murine model 
useful in testing novel therapies 
for malignant gliomas.
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